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Translesion Synthesis Inhibitors as Anti-Cancer Adjuvant Agents 
Abstract 
The translesion synthesis (TLS) pathway is a major mechanism through which cancer 
cells replicate past DNA lesions and promote chemoresistance. TLS allows cancers to survive 
genotoxic chemotherapy and increases the rate of mutation in tumors leading to drug-resistant 
cells. Cancer cells use a set of specialized low-fidelity TLS DNA polymerases to copy over 
lesions with Rev1 serving as a key scaffolding protein. Suppressing Rev1 activity sensitizes 
cancers to genotoxic chemotherapy and reduces the onset of chemoresistance by decreasing 
tumor mutation rate. Disruption of the Rev1/polζ-dependent TLS selective inhibitors has 
demonstrated the ability to sensitize cancer cells to platinating agents and reduce mutagenesis in 
tumors. This study identifies small molecule Rev1/polζ-dependent TLS inhibitors and validates 
the anti-cancer effects of combination cisplatin and TLS inhibitors. Our results demonstrate that 
TLS inhibitors do not have cell death-inducing activity on their own and may have additional 
inhibitory effects on cell proliferation and survival. TLS inhibitors indicate a strong promise for 
an effective and safe adjuvant agents for platinating agents in chemotherapy. 
Introduction 
The TLS pathway is the primary mechanism through which proliferating cells can 
tolerate DNA damage during replication. TLS allows cancers to survive genotoxic chemotherapy 
and increases the rate of mutation in tumors leading to drug-resistant cells. 1-5 Cancer cells use 
TLS DNA polymerases to replicate past DNA lesions and promote chemoresistance. 6 Inhibition 
of TLS has demonstrated the ability to sensitize cancer cells to platinating agents and reduce 
mutagenesis in tumors. Cisplatin is the first line therapy for treating many types of cancers such 
as malignant melanoma and Non-Hodgkin's lymphoma. Although cisplatin is a potent anti-
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cancer agent, cancer cells tend to gain resistance with more exposure to cisplatin and related 
platinum chemotherapy. Combination of therapy with TLS inhibitors may reduce both the dose 
of platinating agents and associated toxic side effects, as well as help avert chemoresistance. 
Therefore, small molecule inhibitors of TLS are emerging as a promising new class of adjuvant 
agents for first-line cancer chemotherapy. 
Within the TLS pathway, cancer cells use a set of specialized low-fidelity TLS DNA 
polymerases to copy over DNA lesions. These multi-protein complexes that act in this process 
are comprised of the Y-family DNA polymerases Rev1, polη, polι and/or polκ and the B-family 
polymerase polζ. Rev1 serves as a key scaffolding protein that assembles active TLS 
polymerases on proliferating cell nuclear antigen. The Rev1 C-terminal domain (Rev1-CT) binds 
Rev1-interacting regions (RIR) from polκ, polι and polη while interacting with the accessory 
Rev7 subunit of polζ. Cells deficient in Rev1 exhibit increased sensitivity to DNA damage and a 
significantly reduced mutation rate. Deletion of the Rev1-CT domain confers a similar 
phenotype, which suggests that this domain is critical for the cellular function of the TLS 
pathway. Finally, suppressing Rev1 activity in vitro and in vivo sensitizes cancers to genotoxic 
chemotherapy and reduces the onset of chemoresistance by decreasing tumor mutation rate. 
Rev1/polζ-dependent TLS selective inhibitors may offer a promising therapeutic strategy 
by sensitizing cancers to genotoxic chemotherapy, reducing the onset of chemoresistance, and 
decreasing tumor mutation rate. The Hadden Lab has identified small molecules that disrupt 
Rev1-CT/Rev3/7 protein-protein interactions using FRET (fluorescence resonance energy 
transfer). This project will validate screening using MTS cell proliferation assay and clonogenic 
assay to determine inhibitory effects of combination cisplatin and TLS inhibitors on cell 
proliferation and survival. 
Chan 6 
Methods 
Two assays were designed to evaluate whether TLS inhibitors increase cell sensitivity 
and avert chemoresistance to cisplatin, respectively: MTS cell proliferation assay and clonogenic 
assay. The cells that were used in these assays were U-2 OS (ATCC® HTB-96™) human 
osteosarcoma cells. The U-2 OS cells were untreated as a negative control, treated with DMSO 
as a vehicle control, and treated with cisplatin as a positive control. U-2 OS cells were suspended 
in U-2 OS growth media, which contains DMEM mixed with penicillin/streptomycin solution, 
and 10% FBS. 
FRET High-throughput Screening 
 FRET high-throughput screening was used to identify which small molecule inhibitors 
interact with Rev1-CT and Rev 7/3. Rev1-CT was conjugated to eCFP and Rev 7/3 was 
conjugated to eYFP. The buffer used in this assay was 10 mM HEPES, 50 mM NaCl at pH 7.4 
and 1% DMSO was to titrate solutions to final concentrations. A stock concentration of 178 µM 
Rev1CT-eCFP was diluted to a final concentration of 2 µM. Stock concentrations of 156 µM or 
132.7 uM Rev7/3-eYFP were diluted to a final concentration of 6.4 µM. Compounds were tested 
at a final concentration of 10 µM using the buffer. Each well in the 384-well plate had a final 
volume of 20 µL. The four controls used were 5 µL each of Rev1-CT-eCFP and Rev7/3-eYFP 
with 10 µL 1% DMSO in FRET buffer, 5 µL each of Rev1-CT-eCFP and Rev7/3-eYFP with 10 
µL of 20 µM unlabeled Rev7/3, 5 µL of Rev1CT-eCFP with 15 µL FRET buffer, and 5 µL of 
Rev7/3-eYFP with 15 µL of FRET buffer. 
5 µL of Rev1-CT-eCFP was added to respective wells with either 10 µL of each 
compound or controls. The plate was covered with aluminum foil and left to incubate for 30 
minutes at 25 °C. Then 5 µL of Rev7/3-eYFP was added to each well. Then plate was covered 
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again and incubated for an additional 10 minutes at 25 °C before reading. The plate was excited 
at 433 nm and read at 2 emissions: 490 nm and 530 nm.  
 To quantify the data, a FRET ratio was determined using the following formula:  
 
 
[!!!!!!!! !!!!!!    where  
 
 
 
The FRET channel represents the value at the 530 nm emission and the donor channel is 
the value at the 490 nm emission. Fa, Fd, and Dd remained the same throughout the calculation 
because they were the control wells. Consequently, the FRET ratios of the compounds were 
compared to the FRET ratio of the unlabeled Rev7/3. Compounds that had a similar or lower 
FRET ratio were considered hits. The IC50 of each compound calculated to measure the 
concentration at which there was 50% inhibition of the Rev7/3 binding to Rev1CT. 
MTS Cell Proliferation Assay 
The MTS cell proliferation assay was used to determine the compounds’ ability to 
increase cell sensitivity to cisplatin. This assay is similar to the MTS cell proliferation assay used 
in project with ITZ analogues. At first, MTS cell proliferation assays were performed to 
determine whether TLS inhibitors had any cell death-inducing activity. TLS inhibitors are not 
intended to demonstrate cell death-inducing activity, because they are used as adjuvant agents to 
cisplatin. The vehicle control was treated with 1% DMSO to account for DMSO used to prepare 
the TLS inhibitors. 3,000 U2-OS cells were seeded in a 96-well plate at 37°C for 24 hours, 
suspended in fresh media, then treated with either DMSO or TLS inhibitors at 50 and 25 µM. 
F = Fret channel 
D = Donor channel 
d = donor sample alone 
a = acceptor alone 
m = mix of donor and acceptor 
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After each of the wells were drugged with respective compounds, the plates were incubated at 
37°C for another 72 hours. 20 µL of a 20:1 MTS and PMS mixture were added to each well and 
incubated at 37°C for 3 hours. The absorbance of each sample was consequently measured using 
a spectrophotometer. Thereafter, the absorbance values were used to calculate percent viability 
of each treatment. After determining TLS inhibitors have no cell death-inducing activity, these 
TLS inhibitors were tested with cisplatin in subsequent experiments to determine whether co-
treatment increases cell sensitivity with cisplatin. 
For the following experiments, U2-OS cells were seeded in a 96-well plate at 37°C for 24 
hours, suspended in fresh media, then the vehicle controls were treated with 1% DMSO and 2% 
DMSO to account for DMSO used to prepare cisplatin and co-treatment with cisplatin and TLS 
inhibitors, respectively. The positive controls were treated with cisplatin at 100, 75, 50, 25, 10, 5, 
1, and 0.5 µM. The experimental wells were treated with cisplatin at these concentrations with 
TLS inhibitors at 50 and 25 µM as well as TLS inhibitors at these concentrations alone. After 
each of the wells were drugged with respective compounds, the plates were incubated at 37°C for 
another 72 hours. 20 µL of a 20:1 MTS and PMS mixture were added to each well and incubated 
at 37°C for 3 hours. The absorbance of each sample was consequently measured using a 
spectrophotometer at 490 nm and these values were used to calculate percent viability of each 
treatment to determine half maximal inhibitory concentration (IC50) of each treatment. 
Clonogenic Assay 
The clonogenic assay is an in vitro cell survival assay that measures the ability of a single 
cell to grow into a colony. 7 This assay was used to determine the compounds’ ability to enhance 
the anti-cancer activity of cisplatin. 1,000 U2-OS cells were seeded in 6-well plates at 37°C for 
24 hours, suspended in fresh media, then the vehicle controls were treated with 1% DMSO and 
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2% DMSO to account for DMSO used to prepare cisplatin and co-treatment with cisplatin and 
TLS inhibitors, respectively. The positive controls were treated with cisplatin at 10 µM and the 
experimental wells were treated with cisplatin at these concentrations with TLS inhibitors at 25 
and 50 µM. After each of the wells were drugged with respective compounds, the plates were 
incubated at 37°C for another 72 hours, suspended in fresh media, and incubated at 37°C for 
another 7 days. After incubation, the media was removed from the plates and a fixative 50% 
methanol and 10% glacial acetic acid was added to the cells for 20 minutes. Then the fixative 
was removed from the plates, and Coomassie Brilliant Blue R-250 in MeOH:AcOH:H2O was 
added (46.5:7:46.5; v/v/v) to the cells. The dye was removed after 20 minutes and colonies ≥ 50 
cells in diameter were scored to determine IC50 of each treatment. 
Results 
FRET High-throughput Screening 
TLS inhibitors 2 (IC50 = 9.2 ± 4.7 µM) and 4 (IC50 = 3.1 ± 2.3) were found to interact 
with Rev1-CT and Rev 7/3 and rescreened to rule out false positives using FRET high-
throughput screening. The other compounds demonstrated in Table 1 were structurally similar to 
compounds 2 and 4 and were selected for additional testing. The IC50 of these compounds were 
calculated as well. All of these compounds moved on to additional in vitro studies in either the 
MTS cell proliferation assay or clonogenic assay.  
MTS Cell Proliferation Assay 
First, TLS inhibitor candidates alone were tested in U2-OS cells at 100, 75, 50, 25 µM 
using the MTS cell proliferation assay to determine whether compounds had cell death-inducing 
activity and the results are demonstrated in Figure 1. Cisplatin, compound 1, demonstrated potent 
cell death-inducing activity at concentrations from 100 µM to 0.5 µM. All of the TLS 
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compounds tested 2, 3, 4, 5, 6, 9, and 10 at all concentrations from 100 µM to 0.5 µM 
demonstrated similar effects in U2-OS cells to DMSO and untreated controls (IC50 > 100), which 
suggests that these TLS inhibitor candidates do not have cell death-inducing activity. These 
candidates progressed to additional studies testing the co-treatment of cisplatin and TLS 
inhibitors in the MTS cell proliferation assay. 
Consequently, cisplatin at concentrations from 100 µM to 0.5 µM and co-treatment of 
cisplatin and TLS inhibitors at 25 µM and 50 µM were tested in U2-OS cells using the MTS cell 
proliferation assay and the results are demonstrated in Figure 2. 
Comparing between the compounds tested, compounds 2, 3, 4, 5, and 6, co-treatment of 
cisplatin and compound 2 at 25 µM (IC50 = 10.54 ± 9.13) was the most potent in inhibiting cell 
viability and at 50 µM (IC50 = 15.5 ± 1.87) demonstrated similar activity. Co-treatment of 
cisplatin and compound 6 at 50 µM (IC50 = 10.58 ± 1.54) was also relatively more potent than 
other treatments, but was the least potent co-treatment of cisplatin and TLS compounds at 25 µM 
(IC50 = 34.63  ± 6.93). Co-treatment of compounds 3, 5, and 6 at 50 µM (IC50 = 19.41 ± 3.03, 
13.86 ± 0.82, 10.58 ± 1.54) were more markedly potent than at 25 µM (IC50 = 27.71 ± 3.70, 
19.08 ± 11.3, 34.63  ± 6.93), which suggests that these compounds are dose dependent. Co-
treatment of cisplatin and compound 4 had similar activity at both concentrations (IC50 at 25 µM 
= 30.77 ± 0.27; IC50 at 50 µM = 30.49 ± 1.96) and was the least potent. Co-treatment with 
compounds 3 and 6 at 50 µM were more potent than cisplatin alone. Co-treatment with 
compounds 2 and 5 at both concentrations were more potent than cisplatin alone. Co-treatment 
with compound 4 at both concentrations was not more potent than cisplatin alone.  
 Comparing between all compounds, co-treatment of cisplatin and compound 10 at 50 µM 
(IC50 = 3.1 ± 1.9) was the most potent and co-treatment at 25 µM (IC50 = 11.0 ± 2.5) was 
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relatively more potent than all other co-treatments at 25 µM. Co-treatment of cisplatin and 
compound 9 at 50 µM (IC50 = 8.6 ± 2.8) was relatively more potent in inhibiting cell viability 
and co-treatment at 25 µM (IC50 = 8.8 ± 1.0) was the most potent of all other co-treatments at 25 
µM. Co-treatment of cisplatin and compound 8 at 25 µM (IC50 = 12.6 ± 6.9) was also relatively 
more potent than all other co-treatments at 25 µM. Co-treatment of cisplatin and compound 7 at 
both concentrations (IC50 at 25 µM = 24.4 ± 6.9; IC50 at 50 µM = 15.3 ± 4.3) and co-treatment of 
cisplatin and compound 8 at 50 µM (IC50 = 19.6 ± 7.5) at had moderate potency compared to all 
other treatments. Co-treatment of compounds 7 and 10 at 50 µM were more markedly potent 
than at 25 µM, which suggests that these compounds are dose dependent. Co-treatment of 
cisplatin and compound 8 and 9 had similar activity at both concentrations. 
These results suggest that most of the TLS inhibitors, except for compound 4, may be 
considered as adjuvant agents to platinating therapy. Treatments with compounds 7, 8, 9, and 10 
advanced to additional studies in the clonogenic assay to assess the compounds’ ability to 
enhance the anti-cancer activity of cisplatin. 
Clonogenic Assay 
 Cisplatin at 10 µM, compounds 7, 8, 9, and 10 alone at 25 µM and 50 µM, and co-
treatment of cisplatin and these compounds were tested in U2-OS cells using the clonogenic 
assay and the results are demonstrated in Figure 3 and 4. All of the tested TLS inhibitors alone 
had similar activity to DMSO, which suggests that these TLS inhibitor candidates do not have 
cell death-inducing activity. These results are comparable to the findings of compounds 9 and 10 
alone (IC50 > 100) in the MTS cell proliferation assay listed in Table 1. Most co-treatments with 
compounds at 25 µM, except compound 9, were more potent than cisplatin alone. Co-treatment 
with compound 8 at 25 µM was the most potent and co-treatment with compound 9 at 25 µM 
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was the least potent compared to other treatments that were tested. All co-treatments with the 
compounds at 50 µM were more potent than cisplatin alone. Co-treatment with compound 7 at 
50 µM was the most potent and co-treatment with compound 9 was the least potent of all other 
treatments. All co-treatments with TLS inhibitors at 50 µM were more potent than co-treatment 
with TLS inhibitors at 25 µM, which suggests that these compounds are dose dependent. Most 
co-treatments with TLS inhibitors at either concentration, except compound 9 at 25 µM, were 
more potent than cisplatin alone. These results suggest that all of the TLS inhibitors that were 
tested may be considered as an adjuvant therapy to platinating agents. 
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Table 1. Cisplatin and TLS Inhibitor Candidates 
 
Compound Structure 
FRET 
IC50 
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Figure 1. MTS cell proliferation assay with cisplatin and TLS inhibitors at concentrations of 25 
µM and 50 µM, respectively. Data represent the Ave ± SEM of at least 2 separate experiments. 
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Figure 2. MTS cell proliferation assay with cisplatin, 1, alone at concentrations from 100 µM to 
0.5 µM and TLS inhibitors, 2, 3, 4, 5, 6, alone at concentrations from 100 µM and 0.5 µM. 
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Figure 3. Clonogenic assay with TLS inhibitors alone and co-treatment of cisplatin with 25 µM 
TLS inhibitors. 
 
Figure 4. Clonogenic assay with TLS inhibitors alone and co-treatment of cisplatin with 50 µM 
TLS inhibitors. 
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Discussion 
 The TLS pathway is a major mechanism cancer cells use to bypass DNA lesions, survive 
genotoxic chemotherapy, and promote chemoresistance. Inhibition of TLS may offer a new 
strategy to sensitize cancer cells to genotoxic chemotherapy, help avert chemoresistance, and 
decrease tumor mutation rate. In the clinical setting, combination therapy with a TLS inhibitor 
may reduce associated toxic side effects and reduce the onset of chemoresistance in cancer 
patients managed on platinating agents. 
By interacting with Rev1-CT and Rev 7/3, TLS candidates were identified using FRET 
high-throughput screening. These compounds were then tested using in vitro cellular assays to 
validate their abilities in inhibiting the TLS pathway. This study explores TLS inhibitors as 
potential adjunct agents to platinating therapy towards increasing cell sensitivity using the MTS 
cell proliferation assay and clonogenic assay, respectively. Our preliminary data demonstrates 
that the TLS inhibitors tested have no cell death-inducing activity alone and several candidates 
provide additional inhibitory effects with platinating agents towards cell viability and survival. 
 In the MTS cell proliferation assay, most of the TLS inhibitors studied, except for 
compound 4, provided additional inhibitory effects to cell proliferation at either one or both 
concentrations, 25 µM and 50 µM. Comparing between all the compounds, most co-treatments 
with compounds at both concentrations, except compound 9 at 25 µM, provided additional 
inhibitory effects to cell proliferation compared to cisplatin alone. These results indicate that 
most of the TLS inhibitors may be promising candidates for adjunctive therapy with platinating 
agents towards increasing cancer cell sensitivity. Platinating agents may be used at lower 
concentrations combined with TLS inhibitors and reduce associated side effects, such as nausea, 
vomiting, adverse hematologic effects, neurotoxicity, and nephrotoxicity. 
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 In the clonogenic assay, all of the TLS inhibitors that were tested may be considered as 
adjuvant agents to platinating therapy. All of the tested TLS inhibitors alone, compound 9 and 
10, had similar activity to DMSO, which indicates that these candidates do not have cell death-
inducing activity similar to findings from the MTS cell proliferation assay. Most co-treatments 
with compounds at both concentrations, except compound 9 at 25 µM, were more potent than 
cisplatin alone and may be promising candidates as adjunct therapy to platinating agents towards 
averting chemoresistance. The addition of TLS inhibitors may reduce cancer cell resistance to 
platinating agents and allow patients to stay on therapy for a longer period of time. 
Altogether, this study demonstrates that TLS inhibitors do not cause cell death-inducing 
activity on their own and are favorable as adjuvant agents. Most of the TLS inhibitors studied 
may be considered as promising adjuvant agents to platinating therapy towards increasing cancer 
cell sensitivity and/ or averting chemoresistance. Overall, TLS inhibitors may be considered as 
safe and effective adjunct agents towards complex regimens involving platinating agents and 
other chemotherapy.
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